Micropuncture technique (MPT) is being adapted nationally to reduce vascular complications (VC). We initiated a quality improvement project in our cath lab to reduce VCs utilizing MPT.
We utilized MPT on all of our non-STEMI femoral artery (FA) access cases starting September 2016. As a comparator group, we collected data from April to August 2016. Anatomic localization of FA and fluoroscopic marking of femoral head was utilized in all cases. VCs were defined by BARC definitions for bleeding/hematomas, retroperitoneal bleed, pseudoaneurysm, AV fistula, arterial thrombosis, distal embolism, dissection, and transient limb ischemia.
A total of 647 patients (Male 357, Female 290; MPT 333) were included in the analysis. MPT as compared to regular 18-gauge needle access did not demonstrate a reduction in VCs (2.4% vs. 2.2%; p = 1.0). MPT utilization did not affect the risk of VCs on univariate (OR 1.08; 95% CI 0.38–3.01; p = 0.88) or multivariate analysis (OR 0.91, 95% CI 0.28–2.93; p + 0.87). Vascular closure device (VCD) utilization as compared to manual/fem-stop hemostasis was the only factor that demonstrated a statistically significant and lower VC rate on both univariate (OR 0.28; 95% CI: 0.08–0.89; p = 0.03), and multivariate (OR 0.24; 95% CI 0.06–0.93; p = 0.039) analysis.
Utilization of MPT in conjunction with fluoroscopic marking of the femoral head and without ultrasound guidance did not contribute to statistically significant reduction in the VC rate. The only factor found to be beneficial is utilization of VCDs. Further large randomized studies are required to demonstrate benefit of routinely utilizing MPT.
- Micropuncture technique remains of unproven benefit in reducing vascular complications.
- We demonstrate this lack of benefit of micropuncture technique in our quality improvement project.
- We need robust objective data to support the nationwide adaptation of micropuncture technique.
Cardiovascular Revascularization Medicine, 2018-10-01, Volume 19, Issue 7, Pages 762-765, Copyright © 2018 Elsevier Inc.